Thera-SAbDab

ROZIPAFUSP

>   Structural Summary
TherapeuticRozipafusp
TargetICOS
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK
100% seqID Fv Structure6x4t [Fvs: BE, DF]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb Fusion
IsotypeG2
Highest Clinical Trial (June '19)Phase-I
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year RecommendedNone
Companies InvolvedAmgen
Conditions Approvedna
Conditions ActiveRheumatoid arthritis
Conditions DiscontinuedSystemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]